Zacks Investment Research Upgrades Esperion Therapeutics Inc. (ESPR) to Hold
Esperion Therapeutics Inc. (NASDAQ:ESPR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.
According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “
Several other brokerages also recently commented on ESPR. Chardan Capital set a $13.00 price objective on shares of Esperion Therapeutics and gave the company a “hold” rating in a research note on Thursday, October 13th. Credit Suisse Group AG upped their price target on shares of Esperion Therapeutics from $10.00 to $14.00 and gave the company an “underperform” rating in a research report on Friday, October 14th. JPMorgan Chase & Co. set a $15.00 price target on shares of Esperion Therapeutics and gave the company a “hold” rating in a research report on Friday, August 5th. Stifel Nicolaus restated a “buy” rating and issued a $30.00 price target (down from $64.00) on shares of Esperion Therapeutics in a research report on Saturday, October 15th. Finally, Barclays PLC set a $13.00 price target on shares of Esperion Therapeutics and gave the company a “hold” rating in a research report on Wednesday, August 31st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $23.39.
Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at 11.99 on Thursday. Esperion Therapeutics has a 52-week low of $9.40 and a 52-week high of $30.41. The company has a 50-day moving average of $12.15 and a 200 day moving average of $12.95. The company’s market capitalization is $270.41 million.
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.05. During the same quarter in the prior year, the company posted ($0.57) earnings per share. Analysts predict that Esperion Therapeutics will post ($3.42) earnings per share for the current year.
In related news, COO Narendra D. Lalwani bought 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 1st. The shares were acquired at an average cost of $9.93 per share, with a total value of $49,650.00. Following the completion of the purchase, the chief operating officer now directly owns 5,000 shares in the company, valued at $49,650. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 35.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ESPR. Jacobs Levy Equity Management Inc. bought a new position in shares of Esperion Therapeutics during the first quarter valued at about $313,000. A.R.T. Advisors LLC raised its position in Esperion Therapeutics by 93.6% in the first quarter. A.R.T. Advisors LLC now owns 200,858 shares of the biopharmaceutical company’s stock worth $3,396,000 after buying an additional 97,112 shares during the period. Bellevue Group AG acquired a new position in Esperion Therapeutics during the first quarter worth $676,000. BVF Inc. IL acquired a new position in Esperion Therapeutics during the first quarter worth $10,261,000. Finally, Squarepoint Ops LLC acquired a new position in Esperion Therapeutics during the first quarter worth $703,000. 64.12% of the stock is currently owned by institutional investors and hedge funds.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.